Oppenheimer restated their outperform rating on shares of Cellectar Biosciences (NASDAQ:CLRB – Free Report) in a report released on Friday morning, Benzinga reports. Oppenheimer currently has a $14.00 target price on the biopharmaceutical company’s stock.
Separately, StockNews.com upgraded Cellectar Biosciences to a sell rating in a research note on Thursday, September 26th.
Check Out Our Latest Research Report on Cellectar Biosciences
Cellectar Biosciences Price Performance
Institutional Trading of Cellectar Biosciences
Large investors have recently added to or reduced their stakes in the business. XTX Topco Ltd raised its holdings in Cellectar Biosciences by 432.4% during the second quarter. XTX Topco Ltd now owns 63,304 shares of the biopharmaceutical company’s stock valued at $158,000 after buying an additional 51,413 shares in the last quarter. AIGH Capital Management LLC raised its stake in shares of Cellectar Biosciences by 8.2% in the 2nd quarter. AIGH Capital Management LLC now owns 3,036,187 shares of the biopharmaceutical company’s stock valued at $7,590,000 after acquiring an additional 231,270 shares in the last quarter. Rosalind Advisors Inc. lifted its holdings in Cellectar Biosciences by 335.4% in the 2nd quarter. Rosalind Advisors Inc. now owns 2,705,616 shares of the biopharmaceutical company’s stock worth $6,764,000 after purchasing an additional 2,084,138 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in Cellectar Biosciences by 146.7% during the first quarter. Vanguard Group Inc. now owns 1,191,081 shares of the biopharmaceutical company’s stock worth $4,741,000 after purchasing an additional 708,191 shares during the period. 16.41% of the stock is owned by institutional investors.
Cellectar Biosciences Company Profile
Cellectar Biosciences, Inc, a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.
Read More
- Five stocks we like better than Cellectar Biosciences
- What Does a Stock Split Mean?Â
- Whirlpool’s High Dividend Yield Is Too Good to Pass Up
- What is the S&P/TSX Index?
- Holiday Spending Boom Ahead: 3 BNPL Stocks Poised for Gains
- With Risk Tolerance, One Size Does Not Fit All
- Boeing: A Perfect Storm of Trouble Is a Loaded Buying Opportunity
Receive News & Ratings for Cellectar Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectar Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.